Overview of glycoprotein IIb/IIIa clinical trials with abciximab and eptifibatide in acute coronary syndromes and percutaneous coronary intervention.
Numerous clinical trials have evaluated the use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). Four studies that looked at abciximab in these settings include the EPIC, EPILOG, CAPTURE, and EPISTENT trials. Two studies that looked at eptifibatide are the IMPACT-II and PURSUIT trials. These studies have demonstrated the benefits of these agents in treating these conditions. This manuscript will provide an overview of these clinical trials and comment on the difficulties of comparing these trials, the problems encountered with subgroup analyses, and provide thoughts on future areas of research that need to be explored.
Teirstein
P
P
Scripps Clinic and Research Foundation, 10666 North Torrey Pines, SW206, La Jolla, CA 92037, USA.
D000077284:Abciximab; D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab